SOURCE: BioProgress PLC

April 29, 2005 09:36 ET

BioProgress plc announces Directorate Change

Cambridgeshire -- (MARKET WIRE) -- April 29, 2005 --

Press Release                                        29 April 2005 

                           BioProgress plc 
                  ("BioProgress" or "the Company") 

                            Director Change

BioProgress plc (AIM: BPRG; NASDAQ: BPRG), announces that Graham Hind has today resigned as Chief Executive Officer and Director of BioProgress.

The Company has appointed Richard Trevillion, currently a Non-Executive Director, to act as interim Chief Executive Officer.

Richard Trevillion joined the Board in February 2005. He is the founder and CEO of Amity Partners Limited, a principal healthcare and technology finance business which has been responsible for numerous transactions since it was formed in late 2002. A qualified solicitor, Mr Trevillion began his career with law firms Lovell White Durrant and Simmons & Simmons, before moving to corporate finance where his senior experience includes being co-Director at Arthur Andersen responsible for their healthcare corporate finance team. Mr Trevillion then became Head of Healthcare within the technology corporate finance group at Close Brothers Corporate Finance in 2000.

The strategic and financial review, which the Board announced on 13 April 2005, is continuing.

                             - Ends - 

Forward-Looking Information.

The Ordinary Shares of BioProgress plc are registered under the US Securities and Exchange Act of 1934. To the extent that this announcement contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, this paragraph applies. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The forward-looking statements in this release include statements addressing future financial and operating results and the timing and benefits of the reorganisation. Detailed information about factors pertinent to the business of the company that could cause actual results to differ is set forth in the Company's filings with the Securities and Exchange Commission. The Company is under no obligation to (and expressly disclaim any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise. This announcement is for information only and does not constitute an offer or invitation to acquire or dispose of any securities or investment advice. The distribution of the announcement and/or issue of securities in certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes are required to inform themselves about and to observe such restrictions.

BioProgress plc                                          
Dan Farrow                           Tel: +44 (0) 1354 655674    

UK Media enquiries: 
Chris Munden / Julian Bosdet         Tel: +44 (0) 20 7398 7700 

US Investor enquiries: 
Taylor Rafferty                                                 
Andrew Saunders                       Tel: +1 212 889 4350 


                      This information is provided by RNS
            The company news service from the London Stock Exchange